Abstract: Liver transplantation is still one of the most effective treatments for endstage liver diseases. Presently,liver transplantation has been widely carried out around China, and a clinical practice guideline is necessary for more standard, effective and safer application of liver transplantation. Therefore, the Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma (HCC) was developed by the experts from Chinese Society of Organ Transplantation; Section of Organ Transplantation, Chinese Society of Surgery; Chinese College of Transplant Doctors. The Chinese clinical practice guideline on liver transplantation for HCC mainly focused on the following 5 parts: recipients selection criteria for liver transplantation, preoperative downstaging treatments, antiviral therapies, applications of immunosuppressant and postoperative treatment for prevention of HCC recurrence. Milan criteria are regarded as the international standard for selecting recipients, while the Hangzhou criteria are a breakthrough for the Milan criteria which is limited to tumor morphology. For patients who are not candidates for liver transplantation or resection, a variety of downstaging treatments can be offered to help them get the chance for liver transplantation. For recipients with hepatitis B virus (HBV) infection, the antiviral treatment should be initiated with the aim to reduce the rate of HBV recurrence after liver transplantation and improve the longterm survival of recipients. Meanwhile, tailored immunosuppression is recommended with the aim of achieving optimal graft function while avoiding undesirable side effects and the recurrence of HCC. For the treatment of HCC recurrence after liver transplantation, several methods including surgery, transcatheter arterial chemoembolization, regional ablation, radioimmunotherapy, target therapy and systemic chemotherapy could be selected for designing the individualized treatment.